Clinical Trials on Stage I Follicular Lymphoma in Italy

Total 116 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Clear Cell Renal Cell Carcinoma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent... and other conditions

United States, Germany, Italy
IRCCS Policlinico S. Matteo

Completed

Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

Italy
Azienda Ospedaliera San Giovanni Battista
Hoffmann-La Roche; University of Turin, Italy; Gruppo Italiano Trapianto di Midollo... and other collaborators

Unknown

Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma

Follicular Lymphoma

Italy
Gruppo Italiano Studio Linfomi

Completed

VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

Non Hodgkin's Follicular Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Terminated

Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma (GAUDEALIS)

Follicular Lymphoma

Italy
Oncology Institute of Southern Switzerland
Azienda Ospedaliero Universitaria Maggiore della Carita; Arcispedale Santa... and other collaborators

Active, not recruiting

Personalized Risk Stratification Model of Follicular Lymphoma Patients

Follicular Lymphoma

Italy, Switzerland
European Hematology Association - Lymphoma Group
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Associazione...

Recruiting

Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry (LUPIAE)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma

Spain, Netherlands, Italy, Croatia, Portugal, Ukraine
SecuraBio

Terminated

Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)

Follicular Lymphoma

France, Italy, Australia, Poland
Gruppo Italiano Studio Linfomi

Completed

Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

Follicular Lymphoma

Italy
University of Bologna

Completed

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy (FM+R-Z)

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

"MIRO" Molecularly Oriented Immuno-radio-therapy (FIL_MIRO)

Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3A

Italy
Paolo Corradini
Annalisa Chiappella; Cristiana Carniti; Anna Dodero

Recruiting

Italian Observational Study on CAR-T Therapy for Lymphoma (CART-SIE)

Follicular Lymphoma | Mantle Cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Diffuse Low Grade B-Cell Lymphoma

Italy
Fondazione Italiana Linfomi - ETS

Recruiting

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial (FIL_FOLL-BIO)

Follicular Lymphoma

Italy
Enterome

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

Follicular Lymphoma | Marginal Zone Lymphoma

United States, Italy, Spain
Novartis Pharmaceuticals

Completed

Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma (LIFT)

Follicular Lymphoma

Spain, Belgium, Canada, Italy, Australia, United States, France
ADC Therapeutics S.A.

Terminated

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States, Belgium, Hungary, Israel, Spain, Switzerland, Poland, France, United Kingdom, Italy
Epizyme, Inc.

Completed

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

B-cell Lymphomas (Phase 1) | Advanced Solid Tumors (Phase 1) | Diffuse Large B-cell Lymphoma (Phase 2) | Follicular Lymphoma (Phase 2) | Transformed Follicular Lymphoma | Primary Mediastinal Large B-Cell Lymphoma

Australia, Canada, France, Germany, Italy, Poland, Taiwan, Ukraine, United Kingdom, United States
Fondazione Italiana Linfomi ONLUS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Unknown

Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (REAL07)

Follicular Lymphoma | Non Hodgkin Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Completed

Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma (FLE09)

Follicular Lymphoma

Italy
Epizyme, Inc.

Recruiting

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular Lymphoma

United States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
SecuraBio

Terminated

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

CD20+ Follicular Lymphoma

Belgium, Italy, United States, Spain, United Kingdom, France
Fondazione Italiana Linfomi - ETS

Active, not recruiting

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Relapsed Follicular Lymphoma

Italy
The Lymphoma Academic Research Organisation
Celgene Corporation

Active, not recruiting

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

Spain, Canada, France, Australia, Italy, Belgium, Germany, Portugal
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (FIL_GAZEBO)

Follicular Lymphoma

Italy
Hoffmann-La Roche

Active, not recruiting

Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) (URBAN)

Follicular Lymphoma

Italy
Gilead Sciences

Completed

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma (ZEUS)

Follicular Non-Hodgkin's Lymphoma Refractory

Spain, France, Ireland, Italy, Greece, Germany, United Kingdom, Sweden, Belgium, Portugal
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA)

Follicular Lymphoma

United States, Spain, Belgium, Japan, Australia, Germany, Italy, Netherlands, Norway, United Kingdom, Austria, France
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Follicular Lymphoma

Italy, Israel, Germany, France, Greece, Spain, Switzerland
Fondazione Italiana Linfomi - ETS

Recruiting

Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Follicular Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Completed

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

Follicular Non-Hodgkin's Lymphoma

Italy
Fondazione Italiana Linfomi ONLUS

Unknown

Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma

Follicular Lymphoma

Italy
Gilead Sciences

Terminated

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Follicular Lymphoma

Spain, Italy, France, Poland, Israel, United Kingdom, Czechia, Romania, Australia, Canada
Lymphoma Study Association

Completed

Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma

Lymphoma, Follicular

France, Italy
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma (OLYMPIA-2)

Follicular Lymphoma (FL)

Spain, United States, Australia, Turkey, Thailand, United Kingdom, Taiwan, Belgium, Poland, Chile, Italy
IGM Biosciences, Inc.
ADC Therapeutics S.A.

Active, not recruiting

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCL

United States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

United States, Australia, Italy
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)

Follicular Lymphoma (FL)

United States, Spain, Taiwan, Israel, Switzerland, Poland, Austria, Turkey, Italy, United Kingdom, Czechia, Australia, Chile
Kite, A Gilead Company

Recruiting

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22)

Relapsed/Refractory Follicular Lymphoma

United States, Spain, United Kingdom, Italy, France, Japan, Germany
Fondazione Italiana Linfomi ONLUS

Completed

Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

Follicular Lymphoma

Italy
Incyte Corporation

Completed

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Lymphoma

Spain, Hungary, United States, Denmark, Italy, Czechia
Pharmacyclics LLC.

Active, not recruiting

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Follicular Lymphoma

United Kingdom, Portugal, Taiwan, Spain, Belgium, Netherlands, Israel, United States, Czechia, Italy, France, Hungary, Australia, Poland, Canada, Austria, Russian Federation, Greece, Turkey
Sandoz
Novartis Pharmaceuticals

Completed

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) (ASSIST_FL)

Follicular Lymphoma

Russian Federation, Netherlands, Peru, United Kingdom, Romania, Brazil, Malaysia, Spain, India, Italy, Bulgaria, Poland, South Africa, Japan, Argentina, Australia, Austria, Colombia, France, Germany, Greece, Hungary, Ireland, Israel, Po... and more
Novartis Pharmaceuticals

Completed

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

United States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Hoffmann-La Roche
AbbVie

Completed

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Follicular Lymphoma

United States, Italy, Canada, Australia, Belgium, United Kingdom, Germany, France
Pfizer

Completed

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Follicular Lymphoma

United States, Spain, United Kingdom, Korea, Republic of, France, Portugal, India, Mexico, Switzerland, Japan, Germany, Romania, Greece, Austria, Belgium, Italy, Thailand, Croatia, Philippines, Russian Federation, Puerto Rico, Ukr... and more
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma

France, Italy, Australia, Canada, Sweden, Switzerland
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL)

Austria, Greece, Israel, Korea, Republic of, Spain, Hungary, Sweden, Switzerland, France, Poland, Taiwan, Australia, Denmark, New Zealand, Turkey, Italy, Netherlands, Belgium, Canada, South Africa, Czechia, Brazil, Germany, Argentina, United... and more
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma (Celestimo)

Relapsed or Refractory Follicular Lymphoma

United States, Korea, Republic of, Taiwan, China, Spain, United Kingdom, Australia, France, Germany, Japan, Turkey, Brazil, Poland, Ukraine, Italy, Russian Federation

Clinical Trials on Stage I Follicular Lymphoma in Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations